Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-18T23:51:37.845Z Has data issue: false hasContentIssue false

4 - Alteplase

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Activase, Cathflo Activase

Generic?

• Yes

Class

• Thrombolytic agent

Commonly Prescribed for

(FDA approved in bold)

Acute ischemic stroke (AIS)

Acute myocardial infarction (AMI)

Pulmonary embolism (PE)

Restoration of function to central venous access device

How the Drug Works

• Alteplase is a tissue plasminogen activator (tPA). It binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, initiating a local fibrinolysis with little systemic effect

How Long Until It Works

• Less than 1 hour, often earlier

If It Works

• After administration, monitor in intensive care – preferably in an acute stroke or cardiac unit

If It Doesn't Work

• Alteplase is not always effective and has risks. After initial monitoring period in intensive care, continue standard AIS, AMI, or PE care

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Alteplase with heparin may improve the clinical course of PE

Tests

• Ensure no contraindications are present before administering drug. For all patients with suspected AIS with onset less than 3 hours prior, immediately type and screen, obtain CBC, glucose, coagulation tests, and ensure no intracranial bleeding (usually with head CT)

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Activating plasminogen increases bleeding risk

Notable AEs

• Superficial bleeding (e.g., at puncture sites), fever, hypotension, dyspnea, nausea, urticaria, and flushing

Life-Threatening or Dangerous AEs

• Internal bleeding (intracranial, GI, GU, or retroperitoneal), anaphylactic reaction, reperfusion arrhythmias, and thrombocytopenia

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• Stop infusion for any serious bleeding. Can use fresh frozen plasma if needed

Best Augmenting Agents to Reduce AEs

• Most AEs cannot be reduced by an augmenting agent

DOSING AND USE

Usual Dosage Range

• 90 mg or less for AIS, 100 mg or less for AMI or PE

Dosage Forms

• Lyophilized powder for injection: 2 mg in 2 mL, 50 mg in 50 mL, 100 mg in 100 mL

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 13 - 16
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Alteplase
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.005
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Alteplase
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.005
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Alteplase
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.005
Available formats
×